Carefusion 303, Inc [2022] APO 40Date:Venue:Delegate:17 June 2022Australian Patent OfficeG PowellBackground Patent...
Home / News / Pearce IP Blog
ALL BLOGS BY
Naomi Pearce
BioBlast® w/e 17 Jun 22: featuring Alvotech’s NASDAQ listing, Samsung Bioepis’ eculizumab, Organon/Henlius’ global biosimilars deal, Sandoz’s citrate-free adalimumab and Innovent’s bevacizumab
11 Jun 22 | Samsung Bioepis presents Ph III eculizumab data Samsung Bioepis presented data from its Ph III trials of...
BioBlast® w/e 10 June 2022: featuring Alvotech/Stada’s adalimumab, Amgen’s rituximab, Fresenius’ tocilizumab IPR, dostarlimab study and Civica’s insulin
02 Jun 22 | Civica selects Profil as clinical trial partner for affordable insulin initiative Civica announced that is...
BioBlast® w/e 03 June 2022: featuring Outlook’s bevacizumab, Lannett’s insulin glargine, Henlius’ biosims, Novartis’ brolucizumab, Roche’s faricimab, Biogen/Samsung Byooviz™ & GBMA Biosimilars Awareness Week
24 May 22 | BR | Shanghai Henlius Biotech signs license agreement for rituximab and trastuzumab biosims Shanghai...
“Method of” treating in the prior art not distinguishable from a “method for” treating
Astellas Pharma Inc. v Aragon Pharmaceuticals, Inc. [2022] APO 36Date:Venue:Delegate:23 May 2022Australian Patent...
BioBlast® w/e 27 May 22 : Prestige’s trastuzumab rejected by CHMP; Additional EU indications for Merck’s Keytruda; Jury trial set in BMS/AstraZeneca patent infringement suit re durvalumab; First patients dosed in Biond Biologics trials for BND-22 (SAR444881); FDA approves Amneal’s Fylnetra™ (biosimilar pegfilgrastim).. and more
20 May 22 | EU | Prestige Biopharma (Roche/Genentech) | HD201, trastuzumab (Herceptin®) Prestige’s trastuzumab...
BioBlast® w/e 20 May 22: Alvotech’s biosim ustekinumab study results, Samsung Bioepis’ biosim ranibizumab approved in KR, Teva/BioEq’s biosim ranibizumab approved in the UK; Celltrion’s PhIII clinical trial for tocilizumab biosim
16 May 22 | Alvotech (Janssen) | AVT04, ustekinumab, (Stelara®)Alvotech announces study results for AVT04, biosimilar...
Intervet inventive step in a veterinary injectable formulation holds on appeal from patent office
Boehringer Ingelheim Animal Health USA Inc. v Intervet International B.V. [2022] FCAFC 88Date:Court:Judges:18 May...
Multiple interlocutory decisions in long-running mining systems infringement cases
Australian Mud Company Pty Ltd v Globaltech Corporation Pty Ltd & Ors (No 2) [2022] FCA 88(experimental evidence)...
Experimental Use Exception Clarified
Jusand Nominees Pty Ltd v Rattlejack Innovations Pty Ltd [2022] FCA 540 Date:Court:Judge:16 May 2022Federal Court of...
Medicinal Cannabis in Australia | Part 5: Making therapeutic claims: advertising and labelling of medicinal cannabis products
Introduction The promotion of medicinal cannabis products presents some specific challenges given that very few such...
Pearce IP BioBlast® w/e 13 May 2022
04 May 22 | Amneal published its Q1 2022 financial results, reporting a 1% increase YoY in net revenue. Amneal...
Too late to challenge amendments once infringement proceedings commenced
Illinois Tool Works Inc v Airco Fasteners Pty Ltd [2022] FCA 495 Date:Court:Judge:5 May 2022Federal Court of...
When supply of a staple commercial product is not infringement
Hood v Down Under Enterprises International Pty Ltd [2022] FCAFC 69Date:Court:Judges:4 May 2022Full Federal Court of...
Medicinal Cannabis in Australia | Part 2: Patient access via the Special Access Scheme (SAS) and Authorised Prescriber (AP) pathways
Introduction As noted in part 1 of our blog series, the vast majority of medicinal cannabis products are not...
Pearce IP BioBlast® w/e 06 May 2022
29 Apr 22 | Merck announced that the EC has approved Keytruda® (pembrolizumab) in combination with chemotherapy (with...